These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 19969433)

  • 41. Quantitative analysis of psilocybin and psilocin in psilocybe baeocystis (Singer and Smith) by high-performance liquid chromatography and by thin-layer chromatography.
    Beug MW; Bigwood J
    J Chromatogr; 1981 Mar; 207(3):379-85. PubMed ID: 7194879
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Determination of psilocybin and psilocin content in multiple Psilocybe cubensis mushroom strains using liquid chromatography - tandem mass spectrometry.
    Goff R; Smith M; Islam S; Sisley S; Ferguson J; Kuzdzal S; Badal S; Kumar AB; Sreenivasan U; Schug KA
    Anal Chim Acta; 2024 Feb; 1288():342161. PubMed ID: 38220293
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Qualitative and quantitative determinations of hallucinogenic components of psilocybe mushrooms by reversed-phase high-performance liquid chromatography.
    Vanhaelen-Fastré R; Vanhaelen M
    J Chromatogr; 1984 Nov; 312():467-72. PubMed ID: 6543215
    [No Abstract]   [Full Text] [Related]  

  • 44. Psychedelic fungus (Psilocybe sp.) authentication in a case of illegal drug traffic: sporological, molecular analysis and identification of the psychoactive substance.
    Solano J; Anabalón L; Figueroa S; Lizama C; Reyes LC; Gangitano D
    Sci Justice; 2019 Jan; 59(1):102-108. PubMed ID: 30654963
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Psilocin identified in a DUID investigation.
    Tiscione NB; Miller MI
    J Anal Toxicol; 2006 Jun; 30(5):342-5. PubMed ID: 16839473
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Screening of hallucinogenic mushrooms with high-performance liquid chromatography and multiple detection.
    Christiansen AL; Rasmussen KE
    J Chromatogr; 1983 Nov; 270():293-9. PubMed ID: 6686235
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Presence of phenylethylamine in hallucinogenic Psilocybe mushroom: possible role in adverse reactions.
    Beck O; Helander A; Karlson-Stiber C; Stephansson N
    J Anal Toxicol; 1998; 22(1):45-9. PubMed ID: 9491968
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Potential therapeutic effects of psilocybin/psilocin are minimized while possible adverse reactions are overrated.
    dos Santos RG
    Ther Drug Monit; 2014 Feb; 36(1):131-2. PubMed ID: 24413570
    [No Abstract]   [Full Text] [Related]  

  • 49. [Automutilation after consumption of hallucinogenic mushrooms].
    Attema-de Jonge ME; Portier CB; Franssen EJ
    Ned Tijdschr Geneeskd; 2007 Dec; 151(52):2869-72. PubMed ID: 18257429
    [TBL] [Abstract][Full Text] [Related]  

  • 50. GLC-mass spectral analysis of psilocin and psilocybin.
    Repke DB; Leslie DT; Mandell DM; Kish NG
    J Pharm Sci; 1977 May; 66(5):743-4. PubMed ID: 559753
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Occurrence of psilocin in Psilocybe baeocystis.
    BENEDICT RG; BRADY LR; TYLER VE
    J Pharm Sci; 1962 Apr; 51():393-4. PubMed ID: 13867140
    [No Abstract]   [Full Text] [Related]  

  • 52. Detecting psychoactive drugs in the developmental stages of mushrooms.
    Gross ST
    J Forensic Sci; 2000 May; 45(3):527-37. PubMed ID: 10855955
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Chemistry and Toxicology of Major Bioactive Substances in
    Patocka J; Wu R; Nepovimova E; Valis M; Wu W; Kuca K
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672330
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Psychoactive mushrooms - an update].
    Supprian T; Frey U; Supprian R; Rösler M; Wanke K
    Fortschr Neurol Psychiatr; 2001 Dec; 69(12):597-602. PubMed ID: 11753749
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Modeling Retention Behavior on Analysis of Hallucinogenic Mushrooms Using Hydrophilic Interaction Liquid Chromatography.
    Rácz N; Nagy J; Jiang W; Veress T
    J Chromatogr Sci; 2019 Mar; 57(3):230-237. PubMed ID: 30535186
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Quantification of psilocin in human whole blood using liquid chromatography-tandem mass spectrometry (LC-MS/MS).
    Gomonit MM; Skillman B; Swortwood MJ
    J Forensic Sci; 2024 Mar; 69(2):678-687. PubMed ID: 38140718
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A survey of hallucinogenic mushroom use, factors related to usage, and perceptions of use among college students.
    Hallock RM; Dean A; Knecht ZA; Spencer J; Taverna EC
    Drug Alcohol Depend; 2013 Jun; 130(1-3):245-8. PubMed ID: 23265089
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Hallucinogenic mushrooms and psilocybine].
    DEYSSON G
    Proc Pharm Soc Egypt; 1960 Jan; 15():27-9. PubMed ID: 24546366
    [No Abstract]   [Full Text] [Related]  

  • 59. DARK Classics in Chemical Neuroscience: Psilocybin.
    Geiger HA; Wurst MG; Daniels RN
    ACS Chem Neurosci; 2018 Oct; 9(10):2438-2447. PubMed ID: 29956917
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Practical aspects of genetic identification of hallucinogenic and other poisonous mushrooms for clinical and forensic purposes.
    Kowalczyk M; Sekuła A; Mleczko P; Olszowy Z; Kujawa A; Zubek S; Kupiec T
    Croat Med J; 2015 Feb; 56(1):32-40. PubMed ID: 25727040
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.